We are proud to share that our Chief Operating Officer, Vanessa Lemarié, has been named in Sifted’s Top 100 Women in Tech in Europe 2025 list, a recognition that celebrates the most impactful and inspiring women shaping the European technology ecosystem.
The annual list, curated by Sifted (backed by the Financial Times) in partnership with Sistafund and Station F, shines a spotlight on founders, investors, operators, and ecosystem builders whose work is driving real change. Nominees are selected based on the scale of their impact, the innovation and significance of their work, their leadership within the community, and their potential to inspire the next generation of leaders in technology.
As Chief Operating Officer at myTomorrows, Vanessa is responsible for business operations in clinical trial patient recruitment, expanded access programs and real-world data. Her work is central to the company’s mission of broadening global access to pre-approval treatments via clinical trials and expanded access programs.
Vanessa champions strategic efficiency gains ensuring quality and compliance is central to the every-day running of the business, whilst reinforcing patient-centricity as a core value. Under her leadership, the myTomorrows Operations teams have launched multiple new programs this year, expanding patient access to treatments, while also reaching a record number of patients supported.
“Working in Healthtech truly means working at an intersection of care and technological advancement. At myTomorrows I’m particularly proud of our team who expertly support patients at every step of their journey with safety, compliance and efficiency top of mind.”
Vanessa Lemarié
Vanessa’s passion for using innovative technology to solve healthcare challenges is also reflected in her previous role as COO at Ada Health, the world’s most popular symptom assessment and care navigation platform. There, she expanded the platform’s global reach and made it more accessible to diverse populations.
Before Ada Health, Vanessa spent 15 years in leadership roles at Bayer Pharmaceuticals, working across most of the company’s franchises. She was the first to launch the company’s partnerships with telemedicine providers in several countries, enabling women to have easier access to trustworthy conversations with qualified healthcare professionals, leveraging nascent technological innovation.
We’re incredibly proud to have Vanessa as part of our mighty team and congratulate her on this prestigious recognition of her achievements.
Michel van Harten 10 Oct 2025